Skip to main content

Table 4 Factors associated with event-free survival of IBS

From: Poor prognostic factors in patients with newly diagnosed intestinal Adamantiades-Behçet’s disease in the Shanghai Adamantiades-Behçet’s disease database: a prospective cohort study

Risk factorHR
(95%CI)
P
Log Rank test risk factor
Male sex0.57 (0.30–1.09)0.09
Onset of BS < 7 years2.25 (1.17–4.33)0.015
WBC > 6.4, × 109/L1.77 (0.94–3.32)0.077
Hb < 123, g/L1.55 (0.83–2.92)0.172
ESR > 24, mm/h2.18 (1.11–4.28)0.024
Biologics0.369 (0.192–0.710)0.003
IFX therapy#0.46 (0.22–0.95)0.035
Poor compliance3.26 (1.73–6.13)0.000
Multiple Cox regression risk factor
Onset of BS < 7 years2.43 (1.24–4.76)0.010
ESR > 24, mm/h1.97 (0.99–3.91)0.053
Poor compliance3.06
(1.61–5.80)
0.001
  1. #IFX therapy was administrated at 0, 2, and 6 weeks (intravenous), and then maintained with the same dosage of IFX every 8 weeks